Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

Share This Post

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent or metastatic cervical cancer who are progressing on or after chemotherapy.

InnovaTV 204, an open-label, multicenter, single-arm clinical trial, was used to gain approval (NCT03438396). In 101 patients with recurrent or metastatic cervical cancer who had had no more than two prior systemic regimens in the recurrent or metastatic context, including at least one prior platinum-based chemotherapy treatment, efficacy was assessed. Sixty-nine percent of patients had previously received bevacizumab as part of a systemic treatment regimen. Tisotumab vedotin-tftv 2 mg/kg was given to patients every 3 weeks until disease progression or unacceptable toxicity.

The primary efficacy outcome measures were the confirmed objective response rate (ORR), as determined by an independent review committee (IRC) using RECIST v1.1, and response duration (DOR). With a median response time of 8.3 months, the ORR was 24 percent (95 percent CI: 15.9%, 33.3 percent) (95 percent CI: 4.2, not reached).

Hemoglobin decreased, fatigue, lymphocytes decreased, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival adverse reactions, haemorrhage, leukocytes decreased, creatinine increased, dry eye, prothrombin international normalised ratio increased, activated partial thromboplastin time prolonged, diarrhoea, and rash were the most common adverse reactions (25 percent), including laboratory abnormalities. A boxed warning for ocular toxicity is included on the product label.

The recommended dose is 2 mg/kg (up to 200 mg for patients under 100 kg) administered as a 30-minute intravenous infusion every three weeks until disease progression or intolerable toxicity.

Take second opinion on cervical cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

Start chat
Need help with cancer treatment?

Welcome to CancerFax.

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

let us know what services would you like to take?

1) Travel abroad for cancer treatment
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation